Zhejiang Jiuzhou Pharm Co Ltd Market Cap ($2.08 Billion)
Market Cap & Net Worth: Zhejiang Jiuzhou Pharm Co Ltd (603456)
Zhejiang Jiuzhou Pharm Co Ltd market cap. Zhejiang Jiuzhou Pharm Co Ltd (SHG:603456) has a market capitalization of $2.08 Billion (CN¥14.25 Billion) as of November 9, 2026. Listed on the SHG stock exchange, this China-based company holds position #5806 globally and #1056 in its home market, demonstrating a 7.38% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zhejiang Jiuzhou Pharm Co Ltd's stock price CN¥16.16 by its total outstanding shares 881710028 (881.71 Million). Also see 603456 operating cash flow for how efficiently the company converts equity into cash flow.
Zhejiang Jiuzhou Pharm Co Ltd Market Cap History (2015–2026)
Zhejiang Jiuzhou Pharm Co Ltd market cap history from 2015 to 2026. Data shows growth from $2.32 Billion to $2.08 Billion (1.01% CAGR). Check Zhejiang Jiuzhou Pharm Co Ltd stock price for real-time trading data and today's change.
Zhejiang Jiuzhou Pharm Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zhejiang Jiuzhou Pharm Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 603456 net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.42x
Zhejiang Jiuzhou Pharm Co Ltd's market cap is 0.42 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.16x
Zhejiang Jiuzhou Pharm Co Ltd's market cap is 3.16 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.42 Billion | $1.65 Billion | $111.48 Million | 0.86x | 12.77x |
| 2017 | $1.03 Billion | $1.72 Billion | $147.61 Million | 0.60x | 6.97x |
| 2018 | $775.99 Million | $1.86 Billion | $157.15 Million | 0.42x | 4.94x |
| 2019 | $1.74 Billion | $2.02 Billion | $237.79 Million | 0.86x | 7.33x |
| 2020 | $4.51 Billion | $2.65 Billion | $380.58 Million | 1.70x | 11.84x |
| 2021 | $7.12 Billion | $4.06 Billion | $633.90 Million | 1.75x | 11.23x |
| 2022 | $5.39 Billion | $5.45 Billion | $921.17 Million | 0.99x | 5.85x |
| 2023 | $3.12 Billion | $5.52 Billion | $1.03 Billion | 0.57x | 3.02x |
| 2024 | $1.77 Billion | $5.16 Billion | $606.10 Million | 0.34x | 2.91x |
| 2025 | $2.31 Billion | $5.51 Billion | $730.07 Million | 0.42x | 3.16x |
Competitor Companies of 603456 by Market Capitalization
Companies near Zhejiang Jiuzhou Pharm Co Ltd in the global market cap rankings as of November 9, 2026. Also see balance sheet size of Zhejiang Jiuzhou Pharm Co Ltd for a full breakdown of the balance sheet.
Key companies related to Zhejiang Jiuzhou Pharm Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #530 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #567 globally with a market cap of $47.07 Billion USD ( CN¥321.69 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #609 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #530 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.61 |
| #567 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $47.07 Billion | CN¥50.43 |
| #609 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.80 |
Market Capitalization of Zhejiang Jiuzhou Pharm Co Ltd (2015–2026)
Market capitalization of Zhejiang Jiuzhou Pharm Co Ltd from 2015 to today. Between 2015 and today, Zhejiang Jiuzhou Pharm Co Ltd's market cap moved from $2.32 Billion to $ 2.08 Billion, with a yearly change of 1.01%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥2.08 Billion | -9.72% |
| 2025 | CN¥2.31 Billion | +30.85% |
| 2024 | CN¥1.77 Billion | -43.49% |
| 2023 | CN¥3.12 Billion | -42.07% |
| 2022 | CN¥5.39 Billion | -24.23% |
| 2021 | CN¥7.12 Billion | +57.87% |
| 2020 | CN¥4.51 Billion | +158.64% |
| 2019 | CN¥1.74 Billion | +124.60% |
| 2018 | CN¥775.99 Million | -24.57% |
| 2017 | CN¥1.03 Billion | -27.72% |
| 2016 | CN¥1.42 Billion | -38.65% |
| 2015 | CN¥2.32 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 8th, 2026 the market cap of Zhejiang Jiuzhou Pharm Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.08 Billion USD |
| MoneyControl | $2.08 Billion USD |
| MarketWatch | $2.08 Billion USD |
| marketcap.company | $2.08 Billion USD |
| Reuters | $2.08 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zhejiang Jiuzhou Pharm Co Ltd
Zhejiang Jiuzhou Pharmaceutical Co., Ltd operates as contract development and manufacturing organization (CDMO) company in China and internationally. The company offers small molecules, drug products, and peptide CDMO services. It also involved in business related to supporting the development of new drugs and pharmaceuticals. It serves global pharmaceutical companies, biotechnology companies, an… Read more